Epigenetics in Cardiovascular Disease
Translational Epigenetics Series

Coordinators: Devaux Yvan, Robinson Emma Louise

Language: English

171.65 €

In Print (Delivery period: 14 days).

Add to cartAdd to cart
Publication date:
498 p. · 19x23.3 cm · Paperback
Epigenetics in Cardiovascular Disease, a new volume in the Translational Epigenetics series, offers a comprehensive overview of the epigenetics mechanisms governing cardiovascular disease development, as well as instructions in research methods and guidance in pursing new studies. More than thirty international experts provide an (i) overview of the epigenetics mechanisms and their contribution to cardiovascular disease development, (i) high-throughput methods for RNA profiling including single-cell RNA-seq, (iii) the role of nucleic acid methylation in cardiovascular disease development, (iv) epigenetic actors as biomarkers and drug targets, (v) and the potential of epigenetics to advance personalized medicine. Here, readers will discover strategies to combat research challenges, improve quality of their epigenetic research and reproducibility of their findings. Additionally, discussion of assay and drug development for personalized healthcare pave the way for a new era of understanding in cardiovascular disease.

SECTION I INTRODUCTORY INFORMATION 1. The ever-growing burden of cardiovascular disease 2. Epigenetics concepts: An overview 3. From classical signaling pathways to the nucleus

SECTION II EPIGENETICS MECHANISMS IN CARDIOVASCULAR DISEASE 4. DNA methylation in heart failure 5. Histone modifications in cardiovascular disease initiation and progression 6. RNA modifications in cardiovascular disease—An experimental and computational perspective 7. Regulatory RNAs in cardiovascular disease 8. Regulation of splicing in cardiovascular disease 9. Cardiac transcriptomic remodeling in metabolic syndrome 10. Sex differences in epigenetics mechanisms of cardiovascular disease 11. Epigenetics in cardiac development and human induced pluripotent stem cells

SECTION III BIOMARKER VALUE 12. Peripheral blood DNA and RNA biomarkers of cardiovascular disease in clinical practice 13. Epigenetics and physical exercise 14. Long noncoding RNAs and circular RNAs as heart failure biomarkers 15. Artificial intelligence in clinical decision-making for diagnosis of cardiovascular disease using epigenetics mechanisms

SECTION IV THERAPEUTIC POTENTIAL 16. Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease

SECTION V METHODOLOGICAL ISSUES 17. Single-cell RNA sequencing in cardiovascular science 18. Good laboratory and experimental practices for microRNA analysis in cardiovascular research 19. Analytical challenges in microRNA biomarker development: Best practices for analyzing microRNAs in cell-free biofluids 20. Concept of biological reference materials for RNA analysis in cardiovascular disease 21. Unbiased bioinformatics analysis of microRNA transcriptomics datasets and network theoretic target prediction

Human geneticists; human genomicists; translational researchers in genomic medicine, epigenetics, cardiovascular disease, biochemistry, and molecular biology; life science researchers; developmental biologists
Dr Devaux is Chairing the EU-CardioRNA COST Action, an international network of 30 European countries focusing on Transcriptomics in Cardiovascular Disease.
Dr Robinson is leading a Working Group on Dissemination activities in the Action. The network, with 100+ individual experts in the field of Epigenetics in cardiovascular disease, constitutes an invaluable reservoir of co-authors for the Volume.
  • Offers a thorough overview of role of epigenetics mechanisms in cardiovascular disease
  • Includes guidance to improve research plans, experimental protocols design, quality and reproducibility of results in new epigenetics research
  • Explores biomarkers and drug targets of therapeutic potential to advance personalized healthcare
  • Features chapter contributions from a wide range of international researchers in the field